company background image
TNYA logo

Tenaya Therapeutics NasdaqGS:TNYA Stock Report

Last Price

US$5.16

Market Cap

US$405.1m

7D

5.3%

1Y

91.1%

Updated

27 Mar, 2024

Data

Company Financials +

Tenaya Therapeutics, Inc.

NasdaqGS:TNYA Stock Report

Market Cap: US$405.1m

TNYA Stock Overview

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.

TNYA fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Tenaya Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Tenaya Therapeutics
Historical stock prices
Current Share PriceUS$5.16
52 Week HighUS$8.09
52 Week LowUS$1.66
Beta2.66
1 Month Change-9.31%
3 Month Change52.21%
1 Year Change91.11%
3 Year Changen/a
5 Year Changen/a
Change since IPO-66.38%

Recent News & Updates

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Recent updates

Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Dec 20
Here's Why We're Watching Tenaya Therapeutics' (NASDAQ:TNYA) Cash Burn Situation

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Mar 07
Tenaya Therapeutics (NASDAQ:TNYA) Will Have To Spend Its Cash Wisely

Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Dec 06
Can Tenaya Therapeutics (NASDAQ:TNYA) Afford To Invest In Growth?

Tenaya Therapeutics gets U.S. FDA clearance for starting human trial of heart failure treatment

Sep 06

Tenaya Therapeutics GAAP EPS of -$0.69 beats by $0.07

Aug 10

Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

Aug 08
Is Tenaya Therapeutics (NASDAQ:TNYA) In A Good Position To Deliver On Growth Plans?

We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Mar 03
We're Hopeful That Tenaya Therapeutics (NASDAQ:TNYA) Will Use Its Cash Wisely

Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Nov 01
Companies Like Tenaya Therapeutics (NASDAQ:TNYA) Are In A Position To Invest In Growth

Tenaya Therapeutics: Treating Heart Disease Through 3 Product Platforms

Aug 06

Shareholder Returns

TNYAUS BiotechsUS Market
7D5.3%0.9%0.4%
1Y91.1%10.3%28.8%

Return vs Industry: TNYA exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: TNYA exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is TNYA's price volatile compared to industry and market?
TNYA volatility
TNYA Average Weekly Movement17.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: TNYA's share price has been volatile over the past 3 months.

Volatility Over Time: TNYA's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016140Faraz Alihttps://www.tenayatherapeutics.com

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

Tenaya Therapeutics, Inc. Fundamentals Summary

How do Tenaya Therapeutics's earnings and revenue compare to its market cap?
TNYA fundamental statistics
Market capUS$405.14m
Earnings (TTM)-US$124.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TNYA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$124.08m
Earnings-US$124.08m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did TNYA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.